- Home
- AMRN vs CTNM Comparison
AMRN vs CTNM Comparison
Compare AMRN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMRN | CTNM |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 328.1M |
| IPO Year | 1993 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMRN | CTNM |
|---|---|---|
| Price | $14.17 | $11.58 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $20.00 |
| AVG Volume (30 Days) | 83.6K | ★ 254.5K |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $3.35 |
| 52 Week High | $20.90 | $15.25 |
Technical Indicators
Market Signals| Indicator | AMRN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 51.09 |
| Support Level | $13.64 | $11.50 |
| Resistance Level | $14.67 | $13.48 |
| Average True Range (ATR) | 0.73 | 0.70 |
| MACD | -0.14 | 0.08 |
| Stochastic Oscillator | 20.10 | 41.51 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.